Pfizer Inc. operates as a research-based, biopharmaceutical company worldwide. The company’s global portfolio includes medicines, vaccines, and medical devices, as well as various consumer healthcare products. Commercial Operations The company manages its commercial operations through two distinct businesses, an Innovative Products business and an Established Products business. Innovative Products Business The Innovative Products business consists of two operating segments, the Global Innovative Pharmaceutical (GIP) segment and the Global Vaccines, Oncology and Consumer Healthcare (VOC) segment. GIP This segment is focused on developing and commercializing novel, value-creating medicines that improve patients’ lives. These therapeutic areas include inflammation, cardiovascular/metabolic, neuroscience/pain, and rare diseases. Certain of the company’s key GIP products include Lyrica (outside all of Europe, Russia, Turkey, Israel and Central Asia countries), Enbrel (outside the United States (U.S.) and Canada), Viagra (U.S. and Canada), BeneFIX, Chantix/Champix, Refacto AF/Xyntha, Xeljanz and Eliquis (jointly developed and commercialized with Bristol-Myers Squibb). The company’s major GIP products and its primary indications include Lyrica GIP for use in the treatment of epilepsy, post-herpetic neuralgia and diabetic peripheral neuropathy, fibromyalgia and neuropathic pain due to spinal cord injury; Enbrel for the treatment of moderate-to-severe rheumatoid arthritis, polyarticular juvenile rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, and nonradiographic axial spondyloarthritis; Viagra GIP for erectile dysfunction; BeneFIX and Refacto AF/Xyntha for hemophilia; Chantix/Champix as an aid to smoking cessation treatment; Genotropin for replacement of human growth hormone; Xeljanz for the treatment of rheumatoid arthritis, Toviaz for overactive bladder; BMP2 for the development of bone and cartilage; Somavert for acromegaly; Rapamune for prevention of organ rejection in kidney transplantation. VOC This segment focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. Consumer Healthcare manufactures and markets various over-the-counter (OTC) products. Certain of the company’s key vaccine products include Prevnar/Prevenar 13, its pneumococcal conjugate vaccine for the prevention of certain types of pneumococcal disease. Its Prevnar family includes vaccines for prevention of pneumococcal disease. Certain of the company’s key oncology products comprise Sutent for the treatment of advanced and/or metastatic renal cell carcinoma, refractory gastrointestinal stromal tumors and advanced pancreatic neuroendocrine tumor; Ibrance as a first-line treatment for certain forms of advanced breast cancer; Xalkori for the treatment of patients with locally advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase-positive; Inlyta for the treatment of patients with advanced renal cell carcinoma after failure of a prior systemic treatment; and FSME-IMMUN/TicoVac as a tick-borne encephalitis vaccine. Major categories and product lines in the company’s Consumer Healthcare business include dietary supplements, such as Centrum brands (including Centrum, Centrum Silver, Centrum Men’s and Women’s, Centrum VitaMints, Centrum Specialist, Centrum Flavor Burst and Centrum Kids), Caltrate and Emergen-C; pain management comprising Advil brands (including Advil, Advil PM, Advil Liqui-Gels, Advil Film Coated, Children’s Advil, Infants’ Advil and Advil Migraine) and ThermaCare; gastrointestinal, such as Nexium 24HR/Nexium Control and Preparation H; and respiratory and personal care, including Robitussin, Advil Cold & Sinus, Advil Sinus Congestion Relief & Pain, Dimetapp and ChapStick. Established Products Business The Established Products business consists of the Global Established Pharmaceutical (GEP) segment. GEP This segment includes legacy brands that have lost or will soon lose market exclusivity in both developed and emerging markets, branded generics, generic sterile injectable products,
pfizer inc (PFE:New York)
235 East 42nd Street
New York, NY 10017
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.
|No competitor information is available for PFE.|
|View Industry Companies|
Sponsored Financial Commentaries
To contact PFIZER INC, please visit www.pfizer.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.